Novartis began construction of a 700,000‑square‑foot manufacturing hub in North Carolina on December 11, 2025, with a groundbreaking ceremony held in Morrisville and Durham. The new complex will create 700 direct jobs by 2030 and support more than 3,000 indirect positions across the U.S. supply chain, underscoring the company’s commitment to expanding its domestic footprint.
The hub is part of a $23 billion U.S. infrastructure investment announced earlier this year, designed to keep all key medicines—particularly the radioligand therapy Pluvicto and the recently FDA‑approved Itvisma—produced domestically. By shifting production away from overseas sites, Novartis aims to reduce supply‑chain risk, accelerate delivery to patients, and strengthen its position as a pure‑play innovative‑medicine company.
Construction is slated to be completed between 2027 and 2028, a timeline that aligns with the company’s broader strategy to scale biologics, sterile packaging, and advanced therapies. The project also benefits from state incentives, including a Job Development Investment Grant, and was attended by FDA Commissioner Marty Makary and North Carolina Governor Josh Stein, highlighting public support for domestic pharmaceutical manufacturing.
"This groundbreaking marks a pivotal step toward delivering all our key medicines for U.S. patients from American soil," said Novartis CEO Vas Narasimhan. "By building a full, end‑to‑end manufacturing presence in North Carolina, we are expanding our capacity to deliver medical breakthroughs, securing a more resilient U.S. supply chain, and investing in the local communities that make our mission possible."
The expansion not only creates jobs but also positions Novartis to meet growing demand for high‑margin therapies while mitigating geopolitical and logistical risks associated with overseas production. The investment signals confidence in the U.S. market and reinforces the company’s long‑term growth trajectory.
With the new hub, Novartis is poised to accelerate the production of its most promising drugs, enhance operational flexibility, and deliver greater value to patients and stakeholders across the country.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.